Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 11.80% is in line with its 1-year average of 11.80%, around the middle of its 1-year range (8.70%–15.33%).
0.04% above its 12-month average of 11.79%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 10.90%.
GROSS MARGIN
11.80%
GROSS MARGIN AVG TTM
11.79%
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+0.04%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
40.32%
median of 765 covered companies
CURRENT VS SECTOR MEDIAN
-70.73%
vs the sector median at left
Lumexa Imaging Holdings, Inc. Common Stock
Market Cap
$1.03B
Gross Margin
11.80%
TTM Avg
11.79%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.04B
Gross Margin
53.74%
TTM Avg
53.23%
3Y Avg
56.54%
5Y Avg
58.23%
Market Cap
$1.04B
Gross Margin
79.71%
TTM Avg
80.13%
3Y Avg
81.57%
5Y Avg
-49.18%
Market Cap
$1.04B
Gross Margin
77.26%
TTM Avg
80.62%
3Y Avg
79.35%
5Y Avg
80.86%
Market Cap
$1.05B
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
16.67%
Market Cap
$1.06B
Gross Margin
73.53%
TTM Avg
70.13%
3Y Avg
70.04%
5Y Avg
68.74%
Market Cap
$996.94M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI) | $1.03B | 11.80% | 11.79% | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.04B | 100.00% | 100.00% | 100.00% | 64.23% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.04B | 53.74% | 53.23% | 56.54% | 58.23% |
| Janux Therapeutics, Inc. (JANX)vs › | $1.04B | 79.71% | 80.13% | 81.57% | -49.18% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | 77.26% | 80.62% | 79.35% | 80.86% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.05B | 0.00% | 0.00% | 0.00% | 16.67% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $1.00B | N/A | N/A | N/A | N/A |
| Teladoc Health, Inc. (TDOC)vs › | $1.06B | 73.53% | 70.13% | 70.04% | 68.74% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $996.94M | 0.00% | 0.00% | 0.00% | 0.00% |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $990.37M | 63.74% | 62.39% | 56.59% | 42.69% |
Gross Margin
11.8%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 10.90% |
| 2026-03-31 | 9.84% |
| 2025-12-31 | 11.10% |
| 2025-09-30 | 15.33% |
| 2025-03-31 | 14.94% |
| 2024-12-31 | 8.70% |
